RadCommonsuma iniciativa da Laudos.AI
RANO · Oncologia
Sistemas/Oncologia

RANO RANO criteria for high-grade glioma response

vigente

Assesses high-grade glioma response on MRI.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
CRPRSDPD

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
Response Assessment in Neuro-Oncology
Versão
2010
Ano
2010
Família
léxico
Tipo de lógica
flat
Modalidade
MRI
Fonte primária
Updated response assessment criteria for high-grade gliomas (RANO) · doi:10.1200/JCO.2009.26.3541
Última verificação
2026-06-22
Última checagem
2026-06-22

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Mostrar a lógica estruturada (JSON)
{
  "categories": [
    "CR",
    "PR",
    "SD",
    "PD"
  ]
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
CR
Complete response
Complete Response (high-grade glioma): all measurable and non-measurable enhancing lesions disappear and remain absent for at least 4 weeks; non-enhancing (T2/FLAIR) disease is stable or improved; the patient is off corticosteroids (or only on physiologic replacement doses); and is clinically stable or improved. All criteria must be met.		——
okfonte
PMC6760341 (Leao et al., 'Standardized MRI assessment of high-grade glioma response: ... the RANO criteria') section 'Definition of radiographic response', CR ('complete disappearance of all enhancing lesions for at least 4 weeks'; 'stable or improved nonenhancing (T2/FLAIR) tumor lesion'; 'off corticosteroids or on physiologic replacement dose only'; 'stable or improved clinically'); cross-checked PMC3631110 Table 1
PR
Partial response
Partial Response: at least a 50% decrease, sustained for >=4 weeks, in the sum of the products of perpendicular diameters (SPD) of all measurable enhancing lesions versus baseline; non-enhancing (T2/FLAIR) disease stable or improved without a higher corticosteroid dose; corticosteroid dose stable or reduced; and clinically stable or improved. All criteria must be met.		——
okfonte
PMC6760341 section 'Definition of radiographic response', PR ('>=50% decrease in SPD of all target lesions compared with baseline measurement for at least 4 weeks'; 'stable or improved nonenhancing (T2/FLAIR) tumor lesion without higher dose of corticosteroids'; 'stable or reduced corticosteroid dose'; 'stable or improved clinically'); cross-checked PMC3631110 Table 1
SD
Stable disease
Stable Disease: does not qualify for CR, PR, or PD; non-enhancing (T2/FLAIR) disease stable without a higher corticosteroid dose; and the patient is clinically stable.		——
okfonte
PMC6760341 section 'Definition of radiographic response', SD ('does not qualify for CR, PD, or PR'; 'stable nonenhancing (T2/FLAIR) tumor lesion without higher dose of corticosteroids'; 'clinically stable status'); cross-checked PMC3631110 Table 1 ('Stable or reduced corticosteroid dose'; 'Clinically stable or improved')
PD
Progression
Progressive Disease (any one of): at least a 25% increase in the SPD of enhancing lesions versus the smallest (nadir) measurement, taken on a stable or increasing corticosteroid dose; a significant increase in non-enhancing (T2/FLAIR) disease not attributable to a lower corticosteroid dose; the appearance of any new lesion; or clear clinical deterioration due to tumor (not explained by a corticosteroid taper or comorbidity).		——
okfonte
PMC6760341 section 'Definition of radiographic response', PD ('>=25% increase in SPD of all target lesions compared with the smallest tumor measurement'; 'significant increase in nonenhancing (T2/FLAIR) tumor lesion without lower dose of corticosteroids'; 'clear clinical deterioration due to tumor, not due to decrease in corticosteroid dose'); new-lesion criterion cross-checked PMC3631110 Table 1

Histórico de versões

Nenhum evento de versão registrado.

Quickstart da APIGET /api/v1/systems/ranoaberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/rano"
Ver documentação completa →